Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/11/2020
SIETES contiene 93161 citas

 
 
 1 a 20 de 829 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al for the ac, et al, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 — Final report. N Engl J Med 2020;383:8 de octubre. [Ref.ID 103731]
2.Enlace a cita original Cita con resumen
Nadkarni GN, Lala A, Bagiella E, Chang HE, Moreno P, Pujadas E, Arvind V, Bose S, Charney AW, Chen MD, Cordon-Cardo C, Dunn AS, Farkouh ME, Glicksberg B, Kia A, Kohli-Seth R, Levin MA, Timsina P, et al.. Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. J Am Coll Cardiol 2020:26 de agosto. [Ref.ID 103709]
3. Cita con resumen
Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll G, McArthur E, Sood MM. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med 2020:8 de junio. [Ref.ID 103655]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103602]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]
6. Cita con resumen
Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial . Circulation 2020;141:enero. [Ref.ID 103503]
7. Cita con resumen
Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Sumilo D, Thomas GN, Toulis KA, Nirantharakumar K. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ 2019;366:3 de septiembre. [Ref.ID 103172]
8.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
9.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
11. Cita con resumen
Chao TF, Chiang CE, Chen TJ, Lip GYH, Chen SA. Reassessment of risk for stroke during follow-up of patients with atrial fibrillation. Ann Intern Med 2019:1 de enero. [Ref.ID 102996]
12.Enlace a cita original Cita con resumen
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]
13. Cita con resumen
Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]
14.Enlace a cita original Cita con resumen
Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein M. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:4 de diciembre. [Ref.ID 102867]
15.Enlace a cita original Cita con resumen
Chuang S-Y, Hsu P-F, Lin F-J, Huang Y-W, Wang G-Z, Chang W-C, Tsai H-J. Association between nonsteroidal anti-inflammatory drugs and atrial fibrillation among a middle-aged population: a nationwide population-based cohort. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102805]
16.Enlace a cita original Cita con resumen
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018;361:4 de julio. [Ref.ID 102751]
17.Enlace a cita original Cita con resumen
18.Enlace a cita original Cita con resumen
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:13 de marzo. [Ref.ID 102547]
19.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]
20.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]
Seleccionar todas
 
 1 a 20 de 829 siguiente >>